Abstract
The p53 gene product is part of a pathway regulating growth arrest at the G1 checkpoint of the cell cycle. Mutation of other components of this pathway, including the products of the ataxia telangiectasia (AT), GADD45, mdm2, and p21WAF1/CIP1 genes may have effects comparable to mutations in the p53 gene. The GADD45 gene is induced by ionizing radiation and several DNA-damaging xenobiotics. Induction requires the binding of wild-type p53 to an evoulutionarily highly conserved putative intronic p53 binding site in intron 3 of GADD45. We recently analyzed the entire coding region of the p53 gene in primary breast cancers of Midwestern white women and found 21 mutations among 53 tumors (39,6%). We now have shown by direct sequencing that there are no mutations in the intronic p53 binding site of the GADD45 gene in any of the 53 primary breast cancers and no mutations in the entire coding region of the GADD45 gene in a subset of 26 consecutive tumors (12 with p53 mutation and 14 without p53 mutation). The only sequence variation detected was a common polymorphism in intron 3. The absence of mutations in the GADD45 gene, including the putative p53-binding intronic site, suggests that this gene is not a frequent target of mutations in breast cancer. Although mutations of the p53 gene have been studied in a wide spectrum of human cancers, GADD45 has not been examined in any tumor or cell line to the best of our knowledge. Our results raise the possibility that mutation of the GADD45 gene alone is not functionally equivalent to loss of wild-type p53 activity.
This is a preview of subscription content, log in via an institution to check access.
References
Canman CE, Wolff AC, Chen CY, et al (1994) The p53-dependent G1-cell cycle checkpoint and ataxia-telangiectasia. Cancer Res 54:5054–5058
Chen CY, Oliner JD, Zhan Q, et al (1994) Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci 91: 2684–2688
El-Deiry WS, Kinzler SE, Pietenpol JA, et al (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45–49
El-Deiry WS, Harper JW, O'Conner PM, et al (1994) WAFT/CPI1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174
Fornace AJ Jr, Nebert D, Hollander MC, et al (1989) Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mot Cell Biol 9: 4196–4203
Fornace AJ Jr, Jackman J, Hollander MC, et al (1992) Genotoxicstress-response genes and growth-arrest genes. GADD45, MyD, and other genes induced by treatment eliciting growth arrest. Ann N Y Acad Sci 663: 139–153
Fritsche M, Haessler C, Brandner G (1993) Induction of nuclear accumulation of the tumor suppressor protein p53 by DNAdamaging agents. Oncogene 8: 307–318
Gatti RA, Boder E, Vinters HV, et al (1991) Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 70: 99–117
Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathology. Cancer Res 54: 4855–4878
Habuchi T, Kinoshita H, Yamada H, et al (1994) Oncogene amplification in urothelial cancer with p53 gene mutation or mdm2 amplification. J Natl Cancer Inst 86: 1331–1335
Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329: 1318–1327
Hartmann A, Blaszyk H, McGovern RM, et al (1995) P53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10:681–688
Hollander MC, Alamo I, Jackman J, et al (1993) Analysis of the mammalian GADD45 gene and its response to DNA damage. J Biol Chem 268: 24385–24393
Kao CC, Yew PR, Berk AJ (1990) Domains required for in vitro association between the cellular p53 and the adenovirus 2EIB 55k proteins. Virology 179: 806–814
Kastan MB, Zhan Q, El-Deiry WS, et al (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597
Kovach JS, McGovern RM, Cassady JD, et al (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 83:1004–1009
Lane DP (1992) P53, the guardian of the genome. Nature 358: 15–16
Li JY, Laurent-Puig P, Salmon RJ, et al (1995) Polymorphism and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10: 599–601
Lianes P, Orlow I, Zhang ZF, et al (1994) Altered patterns of mdm2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86: 1325–1330
Malkin D, Li FP, Strong LC, et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233–1238
Momand J, Zambetti GP, Olson DC, et al (1992) The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245
Oliner JD, Pietenpol JA, Thiagalingam S, et al (1993) Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860
Papathanasiou MA, Kerr NCK, Robbins JH, et al (1991) Induction of the GADD45 gene by ionizing radiation in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol 11: 1009–1016
Price BD, Park SJ (1994) DNA damage increases the levels of mdm2 messenger RNA in wtp53 human cells. Cancer Res 54: 896–899
Reifenberger G, Liu L, Ichimura K, et al (1993) Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739
Rodriguez E, Sreekantaiah C, Chaganti, RSK (1994) Genetic changes in epithelial solid neoplasia. Cancer Res 54: 2298–2306
Saitoh S, Cunningham J, De Vries EMG, et al (1994) p53 gene mutations in breast cancers in Midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9: 2869–2875
Scheffner M, Wemess BA, Huibregtse JM, et al (1990) The E6 oncoprotein encoded by human papilloma-virus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136
Shiohara M, El-Deiry WS, Wada M, et al (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781–3784
Smith ML, Tsuen Chen I, Zhan Q, et al (1994) Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science 266: 1376–1380
Sommer SS, Vielhaber EL (1994) Phage promoter-based methods for sequencing and screening for mutations. In: Mullis KB, Ferre F, Gibbs (eds) Polymerase chain reaction. Birkhäuser, Boston, pp 214–221
Sommer SS, Cunningham J, McGovern RM, et al (1992) Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 84: 246–252
Soussi T, Legros Y, Lubin R, et al (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1–9
Stoflet ES, Koeberl DD, Sarkar G, Sommer SS (1988) Genomic amplification with transcript sequencing. Science 239: 491–494
Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831–1836
Tan TH, Wallis J, Levine AJ (1986) Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol 59: 574–583
Tishler RB, Calderwood SK, Coleman CN, Price BD (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212–2216
Zhan Q, Bae I, Kastan MB, Fornance AJ Jr (1994) The p53-dependent gamma-ray response of GADD45. Cancer Res 54: 2755–2760
Zhan Q, Carrier F, Fornace AJ Jr (1993) Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 13: 4242–4250
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blaszyk, H., Hartmann, A., Sommer, S.S. et al. A polymorphism but no mutations in the GADD45 gene in breast cancers. Hum Genet 97, 543–547 (1996). https://doi.org/10.1007/BF02267084
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02267084